natgillin/translations-raw huggingface dataset:
c CANCIDAS is formulated to provide the full labelled vial dose (70 mg) when 10 ml is withdrawn from the vial.
Zdravilo CANCIDAS je pripravljeno tako, da zagotavlja polni, na viali označeni odmerek (70 mg), če iz viale potegnete 10 ml.
c Caspofungin Accord is formulated to provide the full labeled vial dose (50 mg) when 10 mL is withdrawn from the vial.
Zdravilo Kaspofungin Accord je pripravljeno tako, da zagotavlja polni, na viali označeni odmerek (50 mg), če iz viale potegnete 10 ml.
C Check the tube has opened correctly
C Preverite, da ste tubo pravilno odprli
c Common Terminology Criteria for Adverse Events (CTCAE) version 3.0; grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = life-threatening
c Skupni terminološki kriteriji za neželene dogodke (CTCAE) različica 3.0; stopnja 1 = blaga, stopnja 2 = zmerna, stopnja 3 = huda, stopnja 4 = življenjsko nevarna
C Difference is Eylea group minus active control (laser) group
C) Razlika je vrednost skupine, ki je prejemala zdravilo Eylea minus vrednost aktivne kontrolne skupine (lasersko zdravljenje)
c Duration of response as assessed by an Independent Review Committee d Kaplan-Meier estimate e Assessed by investigator
c Trajanje odziva po oceni odbora za neodvisni pregled d Kaplan-Meierjeva ocena e Ocenjena s strani raziskovalca
c Hazards ratio estimate is based on a Cox model adjusted for stratification factors: ISS staging and number of prior lines. d Log rank test adjusted for stratification factors: ISS staging and number of prior lines. e Median duration of follow up is 11.8 months
c Ocena stopnje tveganja temelji na modelu po Cox-u, prilagojen na osnovi stratifikacijaskih faktorjev: ISS razvrstitvi in številu predhodnih zdravljenj. d Log- rank test prilagojen na osnovi stratifikacijaskih faktorjev: ISS razvrstitvi in številu predhodnih zdravljenj. e Mediano trajanje nadaljevanja zdravljenja je 11,8 mesecev.
c Includes brain natriuretic peptide increased, ventricular dysfunction, left ventricular dysfunction, right ventricular dysfunction, cardiac failure, cardiac failure acute, cardiac failure chronic, cardiac failure congestive, cardiomyopathy, congestive cardiomyopathy, diastolic dysfunction, ejection fraction decreased and ventricular failure, left ventricular failure, right ventricular failure, and ventricular hypokinesia.
c Vključuje zvišano vrednost možganskega natriuretičnega peptida, ventrikularno disfunkcijo, disfunkcijo levega prekata, disfunkcijo desnega prekata, srčno popuščanje, akutno srčno popuščanje, kronično srčno popuščanje, kongestivno srčno popuščanje, kardiomiopatijo, kongestivno kardiomiopatijo, diastolno disfunkcijo, zmanjšanje iztisnega deleža in ventrikularno popuščanje, odpoved levega prekata, odpoved desnega prekata in ventrikularno hipokinezijo.
c Includes patients who were evaluable for response
c Vključuje bolnike, pri katerih je bilo mogoče oceniti odziv
c including drug hypersensitivity, angioedema, bronchospasm, wheezing, dyspnoea, and laryngospasm
c vključno s preobčutljivostjo na zdravilo, angioedemom, bronhospazmom, sopenjem, dispnejo in laringospazmom
c Nominal p-value based on the stratified log-rank test adjusted for stratification factors: β2­microglobulin, albumin, and region d p-value for Response Rate (CR+PR) from the Cochran-Mantel-Haenszel chi-square test adjusted for the stratification factors e Response population includes patients who had measurable disease at baseline f CR=Complete Response; PR=Partial Response.
nominalna p-vrednost na osnovi stratificiranega log-rank testa, prilagojena na osnovi stratifikacijskih dejavnikov: β2-mikroglobulin, albumin in regija. p-vrednost za stopnjo odziva (CR+PR) po Cochran-Mantel-Haenszel hi-kvadratnem testu, prilagojena na osnovi stratifikacijskih dejavnikov
C OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA PROMET Z ZDRAVILOM
c p < 0.01 compared with placebo d Patients with Itch NRS > = 4 at baseline: placebo N = 135, Taltz 80 mg Q4W N = 293, Taltz 80 mg Q2W N = 303, Etanercept N = 306
c p < 0,01 v primerjavi s placebom d Bolniki z oceno srbenja na lestvici NRS > = 4 v izhodišču: placebo N = 135, zdravilo Taltz 80 mg Q4W N = 293, zdravilo Taltz 80 mg Q2W N = 303, etanercept N = 306
c p = 0.002 d PedsQL: The PedsQL Total Scale Score is a general health-related quality of life measure developed for use in children and adolescent populations.
PedsQL: PedsQL je splošno merilo za z zdravjem povezano kakovost življenja pri otrocih in mladostnikih. e p = 0,028
c P=0.083, Humira 0.8 mg/kg versus MTX
c P=0.083, Humira 0,8 mg/kg v primerjavi z MTX
C Subjects (N=22)
preiskovanci s kroničnim hepatitisom C (n = 22)
C Subjects (N=24)
preiskovanci s kroničnim hepatitisom C (n = 24)
c vertigo (spinning feeling);
vrtoglavica (občutek vrtenja);
C) BCVA: Best Corrected Visual Acuity
C) BCVA: najboljša korigirana ostrina vida (Best Corrected Visual Acuity)
C) did not reveal a significant effect of hepatic impairment on the pharmacokinetics of aripiprazole and dehydro-aripiprazole, but the study included only 3 patients with Class C liver cirrhosis, which is insufficient to draw conclusions on their metabolic capacity.
Toda raziskava je vključevala samo 3 bolnike z jetrno cirozo razreda C, kar ne zadošča za sklepe o njihovi presnovni zmogljivosti.
C) LS mean difference and 95% CI based on an ANCOVA model with treatment group, baseline BCVA category (> 20/200 and ≤ 20/200) and region (North America vs.
C) Povprečna razlika najmanjših kvadratov (LS) in 95 % intervala zaupanja (IZ) na podlagi modela ANCOVA z dejavniki kot so zdravljena skupina, izhodiščna vrednost BCVA (> 20/200 in ≤ 20/200) in regija (Severna Amerika vs.
C) LS mean: Least square means derived from ANCOVA model
C) LS: povprečje najmanjših kvadratov, izpeljano z analizo kovariance ANCOVA (Least square means derived from ANCOVA)
C) The difference is the value of the Eylea group minus the value of the ranibizumab group.
C) Razlika je vrednost skupine, ki je prejemala zdravilo Eylea minus vrednost skupine, ki je prejemala ranibizumab.
C-cell hyperplasia and adenoma were seen at all doses in rats and a no observed adverse effect level (NOAEL) could be not defined.
Hiperplazijo celic C in adenome so pri podganah opažali pri vseh odmerkih: ravni brez opaženega neželenega učinka (NOAEL – no observed adverse effect level) ni bilo mogoče opredeliti.
C-reactive protein increased
zvišana C-reaktivna beljakovina
C-reactive protein increased
zvišana koncentracija C-reaktivnega proteina
C-reactive protein increased
zvišana vrednost C-reaktivnega proteina
C-reactive protein increased Blood calcium decreased
zvišana vrednost C-reaktivnega proteina znižana vrednost kalcija v krvi
c-reactive protein increased, blood parathyroid hormone increased
zvišana vrednost C-reaktivnega proteina, zvišana vrednost parathormona v krvi
C-reactive protein, mg/l
C-reaktivni protein, mg/l
C. After the second “click” (or count of 15) lift pre-filled pen from the injection site.
C. Ko boste zaslišali drugi “klik” (ali prešteli do 15), dvignite napolnjeni injekcijski peresnik z mesta za injiciranje.
C. I see an air bubble in my FORSTEO.
C. V mojem injekcijskem peresniku FORSTEO vidim zračni mehurček.
C. inconspicua, and C. guilliermondii, Scedosporium spp., including S. apiospermum, S. prolificans; and Fusarium spp.
C. inconspicua, in C. guilliermondii, za Scedosporium spp., vključno s S. apiospermum in S. prolificans ter za Fusarium spp.
C. inconspicua, C. lipolytica, C. norvegensis, C. pseudotropicalis), Coccidioides immitis, Fonsecaea pedrosoi, and species of Fusarium, Rhizomucor, Mucor, and Rhizopus.
C. inconspicua, C. lipolytica, C. norvegensis, C. pseudotropicalis), Coccidioides immitis, Fonsecaea pedrosoi in vrstam Fusarium, Rhizomucor, Mucor in Rhizopus.
C. inconspicua, C. lipolytica, C. norvegensis, C. pseudotropicalis), Coccidioides immitis, Fonsecaea pedrosoi, and species of Fusarium, Rhizomucor, Mucor, and Rhizopus.
C. inconspicua, C. lipolytica, C. norvegensis, C. pseudotropicalis), Coccidioides immitis, Fonsecaea pedrosoi, in vrstam Fusarium, Rhizomucor, Mucor in Rhizopus.
C. perfringens toxoid
C. perfringens: toksoid
C. perfringens type C toxoid ≥ 20 IU
C. perfringens: toksoid tip C ≥ 20 IE
c.1020 G>A
c.1016 T>G
c.1021 G>A
c.1018 T>C
c.1023 A >C
c.1020 G>A
c.1024 C>T
c.1023 A >C
c.1024C>G
c.1021 G>A
c.1025 G>A
c.1024C>G
c.1025 G>C
c.1024 C>T
c.1025 G>T
c.1025 G>A
c.1031 T>C
c.1025 G>C
c.1034 C>G
c.1025 G>T
c.1042 G>C
c.1031 T>C
c.1045 T>C
c.1034 C>G
c.1046 G>A
c.1042 G>C
c.1048 G>C
c.1045 T>C
c.1054 G>C
c.1046 G>A
c.1055 C>A
c.1048 G>C
c.1065 C>A
c.1054 G>C
c.1069 C>T
c.1055 C>A
c.1072 G>A
c.1065 C>A
c.1081 G>A
c.1069 C>T
c.1088 G>C
c.1072 G>A
c.1095 T>A
c.1081 G>A
c.1115 T>A
c.1088 G>C
c.1115 T>C
c.1095 T>A
c.1115 T>G
c.1115 T>A
c.1117 G>C
c.1115 T>C
c.1118 G>A
c.1115 T>G
c.1124_1129del
c.1117 G>C
c.1124_1129del
c.G1117C
c.1129_1140dup
c.1118 G>A
c.1129_1140dup
c.G1118A
c.1130 C>A
c.1124_1129del
c.1132 T>C
c.1129_1140dup
c.1133 G>A
c.1130 C>A
c.1144T>C
c.1132 T>C
c.1145 G>A
c.1133 G>A
c.1146 C>G
c.1144T>C
c.1151 T>A
c.1145 G>A
c.1153 A>C
c.1146 C>G
c.1156 C>T
c.1151 T>A
c.1157 A>C
c.1153 A>C
c.1165 C>G
c.1156 C>T
c.1166 C>G
c.1157 A>C
c.1166 C>T
c.1165 C>G
c.1181_1183dup
c.1166 C>G
c.1181_1183dup
c.C1166G
c.1187 T>A
c.1166 C>T
c.1192 G>T
c.1181_1183dup
c.1196 G>A or1197 G>A
c.1187 T>A
c.1202 C>G
c.1192 G>T
c.1215 T>A
c.1196 G>A ali1197 G>A
c.1217 A>G
c.1202 C>G
c.1219 A>G
c.1215 T>A
c.1220 T>A
c.1217 A>G
c.1220 T>G
c.1219 A>G
c.140 G>A or 141 G>A
c.140 G>A ali 141 G>A
c.194 G>C (putative splicing site )
c.194 G>C (domnevno mesto za cepitev)
c.194 G>T (putative splicing site )
c.194 G>T (domnevno mesto za cepitev)
c.547 G>A (putative splicing site )
c.547 G>A (domnevno mesto za cepitev)
c.56 T>A
c.53 T>C
c.611 G>A or 612G>A
c.611 G>A ali 612G>A
c.62 T>G
c.61C>T
c.734 G>A or 735G>A
c.734 G>A ali 735G>A
c.779 G>A
c.776 C>G
c.801 G>A (putative splicing site )
c.801 G>A (domnevno mesto za cepitev)
c.860 G>A or 861G>A
c.860 G>A ali 861G>A
c.888 G>A
c.886 A>T
c.893 A>G
c.887 T>C
c.A1023C
c.G1020A
c.A1153C
c.C1146G
c.A1157C
c.A1153C
c.A1217G
c.C1202G
c.A1219G
c.T1215A
c.A893G
c.T887C
c.C1024G
c.G1021A
c.C1024T
c.A1023C
c.C1034G
c.G1025T
c.C1055A
c.G1048C
c.C1065A
c.G1054C
c.C1069T
c.C1055A
c.C1130A
c.1124_1129del
c.C1146G
c.T1144C
c.C1156T
c.T1151A
c.C1165G
c.C1156T
c.C1166G
c.A1157C
c.C1166T
c.C1165G
c.C1202G
c.G1192T
c.G1020A
c.T1016G
c.G1021A
c.T1018C
c.G1025A
c.C1024G
c.G1025C
c.C1024T
c.G1025T
c.G1025A
c.G1042C
c.T1031C
c.G1046A
c.G1042C
c.G1048C
c.T1045C
c.G1054C
c.G1046A
c.G1072A
c.C1065A
c.G1081A
c.C1069T
c.G1088C
c.G1072A
c.G1117C
c.T1115C
c.G1118A
c.T1115G
c.G1133A
c.C1130A
c.G1145A
c.G1133A
c.G1192T
c.1181_1183dup
c.G1196A or G1197A
c.T1187A
c.G194C (putative splicing site )
c.G194C (domnevno mesto za cepitev)
c.G547A (putative splicing site )
c.G547A (domnevno mesto za cepitev)
c.G734A or G735A
c.G734A ali G735A
c.G830A
c.C823T
c.G860A or G861A
c.G860A ali G861A
c.G888A
c.A886T
c.T1018C
c.G1012T
c.T1031C
c.G1025C
c.T1045C
c.C1034G
c.T1095A
c.G1081A
c.T1115A
c.G1088C
c.T1115C
c.T1095A
c.T1115G
c.T1115A
c.T1132C
c.1129_1140dup
c.T1144C
c.T1132C
c.T1151A
c.G1145A
c.T1187A
c.C1166T
c.T1215A
c.G1196A ali G1197A
c.T1220A
c.A1217G
c.T887C
c.A886G
C/ Veguillas – 2 Nave 16, Ajalvir 28864 (Madrid) Spain
C/ Veguillas – 2 Nave 16, Ajalvir 28864 (Madrid) Španija
c/o Vistor hf.
POSTOPEK UPORABE
C08-003A/B N=20
(23-72)1
C0h (ng/ml)
AUC12h (ngh/ml)
C1 is the most important inhibitor of contact activation and regulates the contact system and the intrinsic coagulation pathway by binding to and inactivating kallikrein and factor XIIa.
C1 je najpomembnejši zaviralec kontaktne aktivacije in uravnava kontaktni sistem in intrinzično koagulacijsko presnovno pot, tako da se veže na kalikrein in faktor XIIa in ju inaktivira.
C12: 0 21%
boceprevirja pred naslednjim
C12h: ↑ 3%
C12h: ↑ 3
C12h: ↓ 13%
C12h: ↓ 13
C12h: ↓ 21%
maravirok/emtricitabin
C12hr (nM)
C12ur (nM)
C208 - C216 (QUEST-1 and QUEST-2;
C208 - C216 (QUEST-1 in QUEST-2;
C24 0.89 (0.78, 1.01)
dan)/grazoprevir
C24 1.22 (1.02, 1.45)
Cmax 1,07 (0,88; 1,29)
C24 8.05 (6.33, 10.24)
Cmax 5,27 (4,04; 6,86)
C24  38% (induction of UGT1A1 and CYP3A enzymes)
C24  38% (indukcija encimov UGT1A1 in CYP3A)
C24  39% (Complex binding to polyvalent ions)
C24  39% (Tvori kompleks s polivalentnimi ioni)
C378R
A377_P380dup
C378Y
A377D
C382R
C378R
C382W
C382R
C382Y
C378Y
c: 3 morning, 3 evening d: 3 morning, 4 evening
c: 3 zjutraj, 3 zvečer d: 3 zjutraj, 4 zvečer
C: Giving the injection
Dajanje injekcije
C: observed as uncommon in prevention of atherothrombotic events in patients after an ACS (following percutaneous coronary intervention)
C: opazili občasno pri preprečevanju aterotrombotičnih dogodkov pri bolnikih po AKS (po perkutanem koronarnem posegu)
c: subjects < 75 kg received 100 µg/week peginterferon alfa-2b and subjects ≥ 75 kg received 150 µg/week peginterferon alfa-2b . d: Ribavirin dosing was 800 mg for patients < 60 kg, 1,000 mg for patients 60-75 kg, and 1,200 mg for patients > 75 kg.
c: preiskovanci s telesno maso < 75 kg so prejemali 100 µg peginterferona alfa-2b na teden, preiskovanci s telesno maso ≥ 75 kg pa so prejemali 150 µg peginterferona alfa-2b na teden. d: odmerek ribavirina je znašal 800 mg za bolnike s telesno maso < 60 kg, 1000 mg za bolnike s telesno maso od 60 do 75 kg in 1200 mg za tiste s telesno maso > 75 kg.
c: subjects < 75 kg received 100 µg/week pegylated interferon alfa-2b and subjects ≥ 75 kg received 150 µg/week pegylated interferon alfa-2b. d: ribavirin dosing was 800 mg for patients < 60 kg, 1,000 mg for patients 60-75 kg, and 1,200 mg for patients > 75 kg.
c: preiskovanci s telesno maso < 75 kg so prejemali odmerek 100 µg/teden pegiliranega interferona alfa-2b in preiskovanci s telesno maso ≥ 75 kg so prejemali 150 µg/teden pegiliranega interferona alfa-2b. d: Odmerki ribavirina so bili naslednji: 800 mg za bolnike < 60 kg, 1.000 mg za tiste s telesno maso od 60 do 75 kg in 1.200 mg za bolnike s telesno maso > 75 kg.
C: To mix the recommended number of REYATAZ oral powder sachets with food such as applesauce or yogurt in a small container:
C: Priprava mešanice priporočenega števila vrečic zdravila REYATAZ peroralni prašek s hrano, kot je jabolčna čežana ali jogurt, v manjši posodici:
CA 9-24 n/N (%)
CA 9-12 n/N (%)
CA = continuous abstinence rate; CI = confidence interval; NRT=Nicotine replacement therapy patch
CA  stopnja trajne abstinence; IZ  interval zaupanja; NRT  nadomestno zdravljenje z nikotinskim obližem
CA Wk 9-52
CA 9. - 52. teden
CA Wk 9-52
CA tedni 9-52
CA* wk 13-24
CA* tedni 13-24
CA* wk 13-52
CA* tedni 13-52
Ca-DTPA (Trisodium calcium diethylenetriaminepentaacetate) or
Ca-DTPA (trinatrijev kalcijev dietilentriamin pentaacetat) ali
Ca-DTPA (Trisodium calcium diethylenetriaminepentaacetate) or Ca-EDTA (Calcium disodium ethylenediaminetetraacetate)
Ca-DTPA (trinatrij-kalcijev-dietilentriaminpentacetat) ali Ca-EDTA (kalcijev-dinatrijev-etilendiamintetracetat)
Ca-EDTA (Calcium disodium ethylenediaminetetraacetate)
Ca-EDTA (kalcijev dinatrijev etilendiamin tetraacetat)
Ca-EDTA (Calcium disodium ethylenediaminetetraacetate)
Ca-EDTA (kalcijev dinatrijev etilendiamin tetraacetat).
CA225006: This randomised study in patients with metastatic colorectal cancer who had received initial combination treatment with oxaliplatin plus fluoropyrimidine for metastatic disease compared the combination of cetuximab and irinotecan (648 patients) with irinotecan alone (650 patients).
CA225006: v tej randomizirani študiji so pri bolnikih z metastatskim kolorektalnim rakom, ki so se na začetku zdravljenja metastatske bolezni zdravili s kombinacijo oksaliplatina in fluoropirimidina, primerjali kombinacijo cetuksimaba in irinotekana (648 bolnikov) s samostojnim iritonekanom (650 bolnikov).
CA225025: This randomised study in patients with metastatic colorectal cancer who had received prior oxaliplatin-, irinotecan- and fluoropyrimidine-based treatment for metastatic disease compared the addition of cetuximab as a single agent to best supportive care (BSC) (287 patients) with best supportive care (285 patients).
CA225025: v tej randomizirani študiji so pri bolnikih z metastatskim kolorektalnim rakom, ki so predhodno prejemali zdravljenje na osnovi oksaliplatina, iritonekana in fluoropirimidina, primerjali dodajanje cetuksimaba kot samostojnega zdravila k najboljši podporni oskrbi (NPO) (287 bolnikov) z najboljšo podporno oskrbo (285 bolnikov).
cabamazepine, phenytoin (medicines to treat epilepsy or other illness). warfarin, dipyridamole, phenprocoumon, low-dose acetylsalicylic acid (blood thinning medicines).
karbamazepin, fenitoin (zdravili za zdravljenje epilepsije ali drugih bolezni). varfarin, dipiridamol, fenprokumon, majhni odmerki acetilsalicilne kisline (zdravila za redčenje krvi).
Cabazitaxel AUC: ↑ 1.3-fold
Kabazitaksel AUC: ↑ 1,3-krat
Cabazitaxel works by blocking the ability of cancer cells to break down their internal ‘skeleton’ that allows them to divide and multiply.
Cabazitaksel deluje tako, da zavira sposobnost rakavih celic za razgradnjo njihovega notranjega „ogrodja“, ki jim omogoča, da se delijo in množijo.
cabergoline lisuride, pergolide: risk of vasoconstriction and increase in blood pressure.
kabergolinom, z lisuridom, pergolidom: tveganje za vazokonstrikcijo in povišan krvni tlak.
CABG-related bleeding
Krvavitev, povezana z aortokoronarnim obvodom (CABG)
CABG: Coronary Artery Bypass Graft Surgery; GUSTO: Global Use of Strategies to Open Coronary Arteries; w/o: without a In the CHAMPION pooled analysis, GUSTO Mild was defined as other bleed not requiring blood transfusion or causing haemodynamic compromise b In CHAMPION PHOENIX, GUSTO Mild was defined as other bleeding requiring intervention but not requiring blood transfusion or causing haemodynamic compromise
CABG: kirurški poseg aortokoronarnega obvoda (Coronary Artery Bypass Graft); GUSTO: Globalna uporaba strategij za odpiranje okludiranih arterij (Global Use of Strategies to Open Occluded Arteries) a V združeni analizi CHAMPION je bil blagi dogodek GUSTO opredeljen kot druga krvavitev, zaradi katere ni bila potrebna transfuzija krvi, in ki ni ogrozila hemodinamike b V analizi CHAMPION PHOENIX je bil blagi dogodek GUSTO opredeljen kot druga krvavitev, zaradi katere je bil potreben ukrep, vendar ni bila potrebna transfuzija krvi, in ki ni ogrozila hemodinamike
CABOMETYX (cabozantinib) tablets and COMETRIQ (cabozantinib) capsules are not bioequivalent and should not be used interchangeably (see section 5.2).
Zdravilo CABOMETYX (kabozantinib) tablete in COMETRIQ (kabozantinib) kapsule nista bioekvivalentni, zato se ju ne sme prosto zamenjevati (glejte poglavje 5.2).
CABOMETYX 20 mg film-coated tablets are yellow, round with no score, and identified with “XL” on one side and “20” on the other side.
Zdravilo CABOMETYX 20 mg filmsko obložene tablete so rumene, okrogle, brez razdelilne zareze, identificirane z "XL" na eni strani in "20" na drugi strani tablete.
CABOMETYX 20 mg film-coated tablets cabozantinib
CABOMETYX 20 mg filmsko obložene tablete kabozantinib
CABOMETYX 20 mg film-coated tablets: Each tablet contains cabozantinib (S)-malate equivalent to 20 mg of cabozantinib.
Zdravilo CABOMETYX 20 mg filmsko obložena tableta vsebuje kabozantinib (S)-malat, kar ustreza 20 mg kabozantiniba.
CABOMETYX 40 mg film-coated tablets cabozantinib
CABOMETYX 40 mg filmsko obložene tablete kabozantinib
CABOMETYX 40 mg film-coated tablets: Each tablet contains cabozantinib (S)-malate equivalent to 40 mg of cabozantinib.
Zdravilo CABOMETYX 40 mg filmsko obložena tableta vsebuje kabozantinib (S)-malat, kar ustreza 40 mg kabozantiniba.
CABOMETYX 60 mg film-coated tablets cabozantinib
CABOMETYX 60 mg filmsko obložene tablete kabozantinib
Cabometyx 60 mg film-coated tablets EU/1/16/1136/005
CABOMETYX 60 mg filmsko obložene tablete EU/1/16/1136/005
CABOMETYX 60 mg film-coated tablets: Each tablet contains cabozantinib (S)-malate equivalent to 60 mg of cabozantinib.
Zdravilo CABOMETYX 60 mg filmsko obložena tableta vsebuje kabozantinib (S)-malat, kar ustreza 60 mg kabozantiniba.
Cabometyx can only be obtained with a prescription and treatment should be started by a doctor who has experience in using cancer medicines.
Predpisovanje in izdaja zdravila Cabometyx je le na recept, zdravljenje z njim pa sme uvesti le zdravnik, ki ima izkušnje z uporabo zdravil za zdravljenje raka.
Cabometyx contains the active substance cabozantinib.
Zdravilo Cabometyx vsebuje zdravilno učinkovino kabozantinib.
Cabometyx has been investigated in one main study involving 658 adults with advanced renal cell carcinoma that had got worse despite treatment with a VEGF inhibitor.
Zdravilo Cabometyx so raziskali v eni glavni študiji, ki je vključevala 658 odraslih z napredovalim karcinomom ledvičnih celic, ki se je poslabšal kljub zdravljenju z zaviralcem VEGF.
CABOMETYX is a cancer medicine that contains the active substance cabozantinib.
Zdravilo CABOMETYX je zdravilo proti raku, ki vsebuje učinkovino kabozantinib.
Cabometyx is a cancer medicine used to treat adults with advanced renal cell carcinoma (a type of kidney cancer) who have been previously treated with a type of cancer medicine called a ‘vascular endothelial growth factor (VEGF) inhibitor’.
Cabometyx je zdravilo proti raku, ki se uporablja za zdravljenje odraslih z napredovalim karcinomom ledvičnih celic (vrsto raka ledvic), ki so bili predhodno zdravljeni z vrsto zdravila za zdravljenje raka, ki se imenuje „zaviralec endotelijskega rastnega faktorja v žilah (VEGF)“.
CABOMETYX is for oral use.
Zdravilo CABOMETYX se jemlje peroralno.
CABOMETYX is indicated for the treatment of advanced renal cell carcinoma (RCC) in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy
Zdravilo CABOMETYX je indicirano za zdravljenje odraslih bolnikov z napredovalim karcinomom ledvičnih celic (KLC) po predhodnem ciljnem zdravljenju z endotelijskim rastnim faktorjem v žilah (VEGF, vascular endothelial growth factor).
CABOMETYX should be taken once a day.
Zdravilo CABOMETYX jemljite enkrat na dan.
CABOMETYX should not be taken with food.
Zdravila CABOMETYX ne smete jemati s hrano.
CABOMETYX tablets are available in packs containing either 4 blisters with 7 tablets each (28 total), or one plastic bottle with 30 tablets.
Zdravilo CABOMETYX tablete je na voljo v pakiranjih, ki vsebujejo 4 pretisne omote s po 7 tabletami (skupaj 28) ali eno plastenko s 30 tabletami.
Cabometyx was shown to significantly improve the time these patients lived without their disease getting worse.
Izkazalo se je, da zdravilo Cabometyx znatno izboljša čas, ko so bolniki živeli brez poslabšanja bolezni.
Cabozantinib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs) implicated in tumour growth and angiogenesis, pathologic bone remodeling, drug resistance, and metastatic progression of cancer.
Kabozantinib je majhna molekula, ki zavira več receptorjev tirozin-kinaze (RTK), ki povzročajo rast tumorja in angiogenezo, patološko preoblikovanje kosti, odpornost na zdravilo in metastatsko napredovanje raka.
Cabozantinib is not recommended for use in subjects with severe hepatic impairment as safety and efficacy have not been established in this population.
Uporaba kabozantiniba se ne priporoča pri bolnikih s hudo jetrno okvaro, saj varnost in učinkovitost pri tej populaciji nista bili dokazani.
Cabozantinib should be discontinued in patients who develop an acute myocardial infarction or any other clinically significant arterial thromboembolic complication.
Z uporabo kabozantiniba je treba prenehati pri bolnikih, pri katerih se razvije akutni miokardni infarkt ali drugi klinično pomembni znaki zapletov arterijske trombembolije.
Cabozantinib should be discontinued in patients who experience a GI perforation or a fistula that cannot be adequately managed .
Uporabo kabozantiniba je treba pri bolnikih, pri katerih se pojavi gastrointestinalna perforacija ali fistula, ki je ni možno ustrezno obravnavati, prekiniti.
Cabozantinib should be discontinued in patients who experience ONJ.
Pri bolnikih, pri katerih se pojavi osteonekroza čeljusti, je treba z uporabo kabozantiniba prekiniti.
Cabozantinib treatment should be discontinued in patients with RPLS.
Pri bolnikih z RPLS je treba z zdravljenjem s kabozantinibom prenehati.